Skip to content
News
Anal Cancer
Bladder Cancer
Bone Cancer
Brain Cancer
Breast Cancer
Cancer of Unknown Primary
Cervical Cancer
Colon Cancer
Esophageal Cancer
Gastric Cancer
GIST
Head & Neck Cancer
Hodgkins Lymphoma
Leukemia
Acute Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Liver Cancer
Lung Cancer
Melanoma
Mesothelioma
Multiple Myeloma
Myelodysplastic Syndrome
MPN-PV-ET-MF
Neuroblastoma
Neuroendocrine Tumors
Non Hodgkins Lymphoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cancer
Rectal Cancer
Sarcoma
Skin Care
Skin Cancer
Testicular Cancer
Thyroid Cancer
Triple Negative Breast Cancer
Uterine Cancer
About Us
Advertising
News
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Search
Acute Leukemia
May 15, 2026
FDA Approves First All-Oral Combination Option for Certain Patients With Newly Diagnosed AML
Dr. C H Weaver MD
November 21, 2025
New Targeted Drug Approved for Certain Adults With Relapsed or Refractory AML With an NPM1 Mutation
Dr. C H Weaver MD
November 6, 2025
FDA Approves New Targeted Therapy Revuforj for Hard-to-Treat Acute Myeloid Leukemia
Dr. C H Weaver MD
November 18, 2024
FDA Approves Breakthrough Leukemia Treatment Revuforj (Revumenib)
Dr. C H Weaver MD
October 8, 2024
FDA Expands Blincyto Approval in Frontline B-Cell Precursor Acute Lymphoblastic Leukemia
Dr. C H Weaver MD
April 17, 2024
Acute Myeloid Leukemia: Overview and Treatment
Dr. C H Weaver MD
October 25, 2023
Tibsovo for Treatment of Acute Myeloid Leukemia
Dr. C H Weaver MD
March 22, 2023
Revumenib Shows Promise in Acute Leukemia
Dr. C H Weaver MD
October 29, 2022
FDA Approves Pemazyre for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Dr. C H Weaver MD
March 30, 2022
Pemazyre for FGFR1-Mutant Myeloid, Lymphoid Neoplasms
Dr. C H Weaver MD
March 3, 2021
Blincyto Prolongs Survival in Acute Lymphoblastic Leukemia (ALL)
Dr. C H Weaver MD
January 12, 2021
Vidaza Provide Alternative Treatment for Transplant Ineligble AML
Dr. C H Weaver MD
1
2
3
…
9
Next Page
Loading Comments...
Write a Comment...
Email (Required)
Name (Required)
Website
